Drug interactions
Fedratinib + Ruxolitinib
Severity: Major
Fedratinib and Ruxolitinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Fedratinib inhibits CYP3A4 and may raise ruxolitinib exposure. Both are JAK inhibitors, so combined use adds pharmacodynamic myelosuppression and infection risk and has no established therapeutic rationale.
What this interaction means in plain words
Fedratinib and Ruxolitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Fedratinib belongs to Oncology; Ruxolitinib belongs to Oncology.
Why it happens
Fedratinib inhibits CYP3A4 metabolism of ruxolitinib, with overlapping JAK inhibition.
What to do
Avoid concurrent use of these two JAK inhibitors. If unavoidable, monitor blood counts closely and reduce the ruxolitinib dose.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Fedratinib and Ruxolitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Ruxolitinib
Other interactions of Fedratinib
- Fedratinib + Thioridazine Contraindicated
- Amobarbital + Fedratinib Major
- Apalutamide + Fedratinib Major
- Brexpiprazole + Fedratinib Major
- Carbamazepine + Fedratinib Major
- Chloramphenicol + Fedratinib Major
Frequently asked questions
Can I take Fedratinib with Ruxolitinib?
MediHelp rates the interaction as major. Fedratinib and Ruxolitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Fedratinib inhibits CYP3A4 and may raise ruxolitinib exposure. Both are JAK inhibitors, so combined use adds pharmacodynamic myelosuppression and infection risk and has no established therapeutic rationale.
How serious is the interaction between Fedratinib and Ruxolitinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use of these two JAK inhibitors. If unavoidable, monitor blood counts closely and reduce the ruxolitinib dose.
What other medicines interact with Ruxolitinib?
MediHelp also lists interactions of Ruxolitinib with, for example, Atazanavir, Ceritinib, Chloramphenicol. The full list is on the Ruxolitinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
